Royal London Asset Management Ltd. Cuts Stake in West Pharmaceutical Services, Inc. $WST

Royal London Asset Management Ltd. trimmed its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 15.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,818 shares of the medical instruments supplier’s stock after selling 15,732 shares during the period. Royal London Asset Management Ltd.’s holdings in West Pharmaceutical Services were worth $30,091,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of WST. Addison Advisors LLC purchased a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth approximately $28,000. Avalon Trust Co bought a new position in West Pharmaceutical Services in the second quarter worth approximately $28,000. Elyxium Wealth LLC purchased a new stake in West Pharmaceutical Services during the fourth quarter worth $25,000. Bayban bought a new stake in West Pharmaceutical Services during the 4th quarter valued at $27,000. Finally, DV Equities LLC bought a new position in shares of West Pharmaceutical Services in the 4th quarter worth $28,000. Institutional investors own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on WST shares. Evercore reiterated an “outperform” rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Stephens reissued an “overweight” rating and set a $360.00 price target on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. TD Cowen restated a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. BNP Paribas Exane assumed coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They issued an “outperform” rating and a $447.00 price objective on the stock. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $368.08.

West Pharmaceutical Services Stock Down 2.3%

West Pharmaceutical Services stock opened at $338.21 on Friday. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $386.00. The business has a fifty day moving average price of $350.55 and a 200-day moving average price of $303.61. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The stock has a market capitalization of $23.80 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 2.36 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same period in the prior year, the company posted $1.84 EPS. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities research analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were issued a dividend of $0.22 per share. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is 11.27%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.